Type 2 Diabetes
Pipeline by Development Stage
Drug Modality Breakdown
Type 2 Diabetes is a ~$4.1B Part D market dominated by two next-generation classes (GLP-1 agonists and dual GIP/GLP-1 agonists) in peak commercial phase.
Key Trends
- GLP-1 and dual-agonist therapies rapidly consolidating market share from older mechanisms
- Mounjaro (tirzepatide) emerging as category leader with 58% MoA share; competitive intensity driving innovation
- Strong clinical trial activity (1,557 trials) indicates pipeline focus on combination therapies and next-gen formulations
Career Verdict
Excellent career opportunity: the market is mature but undergoing class-level disruption, creating demand for specialists in commercialization, medical affairs, and outcomes research around newer mechanisms.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | MOUNJARO (tirzepatide) | Eli Lilly and Company | $2.4B | 58% | PEAK | Growing | 15.4yr |
| 2 | RYBELSUS (oral semaglutide) | Novo Nordisk | $1.7B | 41% | PEAK | Stable | 12.6yr |
Drug Class Breakdown
rapidly growing, market-shifting category
stable with oral formulation expansion
declining, niche positioning
Career Outlook
GrowingType 2 Diabetes is a high-opportunity area for mid- to senior-level talent, driven by mature market dynamics, class-level competition, and sustained pipeline innovation. The shift from older small molecules (sulfonylureas, thiazolidinediones) to GLP-1/GIP agonists is creating urgent demand for specialists who understand obesity co-indication strategy, combination therapy positioning, and biosimilar defense. Entry-level roles are abundant in Commercial, while senior roles in Medical Affairs and Health Economics are less saturated.
Breaking In
Target Commercial or Clinical Operations roles at Eli Lilly, Novo Nordisk, or Sanofi; GLP-1 expertise is a fast-track credential for promotion to senior brand or MSL roles.
For Experienced Professionals
Senior professionals should position for Medical Affairs, outcomes research, or obesity portfolio expansion roles; the 2039–2041 patent cliff window creates C-suite visibility for pipeline transition planning.
In-Demand Skills
Best For
Hiring Landscape
Type 2 Diabetes hiring is concentrated in Commercial roles (569 jobs, $266K avg) and Engineering (485 jobs), reflecting market maturity and manufacturing scale-up for injectables. Top hiring companies include Sanofi (952 jobs), GE HealthCare (958 jobs), and Merck (558 jobs), though direct indication-specific staffing data is limited. Clinical Operations roles offer highest compensation ($356K avg) but lowest volume (176 jobs).
By Department
Commercial and Clinical Operations roles dominate hiring; specialists in injectable formulation commercialization and payer outcomes can command $280K+ salaries.
On Market (13)
Approved therapies currently available
Competitive Landscape
100 companies ranked by most advanced pipeline stage
+70 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 8,421 patients across 50 trials
Effects of D-Chiro-Inositol Combined with Metformin on Insulin Resistance in People with Overweight or Obesity and T2DM
Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan
Mechanism of SGLT2 Inhibition in the Kidney
DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes
A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)
A Study of A Novel Approach to Titrate Basal Insulin (LY2963016) in Participants With Type 2 Diabetes
Combined Active Treatment in Type 2 Diabetes with NASH
Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D
Semaglutide Treatment On Coronary Progression
MAGE of Anagliptin Compared With Sitagliptin With Type 2 Diabetes Mellitus
The Effect of a SGLT2 Inhibitor on Glucose Flux, Lipolysis and Exercise in Type 2 Diabetes
Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes
A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes
Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?
A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes
Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes
Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes
Dapagliflozin Effects on Epicardial Fat
Sitagliptin and Glucagon Counterregulation
Linagliptin's Effect on CD34+ Stem Cells
The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion
Effects of Sitaglpitin on Endothelial Function During the OGTT in T2DM
Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes
Liraglutide Hospital Discharge Trial
Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride
Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients
Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes
Blood Pressure Outcomes With Liraglutide Therapy
FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)
Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes
Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)
Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both Medications
Effects of DPP-4 Inhibition on Triglycerides
Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes
Efficacy and Tolerability of Saxagliptin add-on Compared to Uptitration of Metformin in Patients With Type 2 Diabetes
The Effect of Welchol on Glucose Metabolism in Type 2 Diabetics
Aggressive Versus Conservative Blood Glucose Control in Hospitalized Type 2 Diabetic Patients Using Detemir and Aspart Insulin
Levemir-Body Composition and Energy Metabolism
Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat Type 2 Diabetes
Bone Turnover in Type 2 Diabetes Patients
Effect of Dipeptidyl Peptidase-IV Inhibitor and Sulfonylurea on Glucose Variability and Oxidative Stress
18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics
The Copenhagen Insulin and Metformin Therapy Trial
Prospective Influence of Bedtime Insulin Glargine on Mobilization and Function of Endothelial Progenitor Cells
Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes
Related Jobs in Metabolic Diseases
Sr. Product Marketing Manager – Consumer - (HYBRID - ACTON, MA OR SAN DIEGO, CA)
Senior Data Engineer, Reliability & Observability (Hybrid - Acton, MA)
Sr Manager, Data Engineering
Sr Scientist, Drug Metabolism
Manager, Financial Planning and Analysis
Health Economics & Outcomes Research Sr Manager, Obesity
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.